Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma.

Ines B MenjakEvelyn S EliasSheena JainDeborah LawrieTeresa M Petrella

Published in: JCO oncology practice (2021)

Ipilimumab is associated with high rates of toxicity; however, a proactive nurse-led monitoring program was feasible and patients had low rates of grade 3-4 toxicity. Hospitalization rates and ER visits remained high; however, the minority of those were related to drug toxicity.

Keyphrases

oxidative stress
quality improvement
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
primary care
oxide nanoparticles
peritoneal dialysis
patient reported outcomes